Ipatasertib is an orally active, potent and selective Akt inhibitor with antitumor activity. Inhibition of Akt activity by Ipatasertib resulted in blockade of cell-cycle progression and reduced viability of cancer cell lines. Markers of Akt activation, including high-basal phospho-Akt levels, PTEN loss, and PIK3CA kinase domain mutations, correlate with sensitivity to Ipatasertib.

1489263-16-2

C24H33Cl2N5O2

494.46

RG-7440;GDC-0068;RG 7440;GDC0068;GDC 0068;RG7440;Ipatasertib HCl

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years